Surgery Partners shareholders entered November with a concrete $23.50-per-share cash offer from HealthSpan Partners, an affiliate of Bon Secours Mercy Health, after the companies announced a definitive take-private deal valued at roughly $5.7 billion in enterprise value and the stock’s largest one-day jump in years.

What holders own today

Surgery Partners operates short-stay surgical facilities across dozens of states, and the buyer pitches the combination as one of the largest outpatient surgical platforms in the country. Bain Capital, which filings describe as a major existing investor, is expected to roll part of its stake into the acquiring group rather than exit entirely on day one. Until regulators and shareholders sign off, SGRY remains listed on Nasdaq and trades as a merger-arbitrage story around the stated price.

Market data from the announcement week showed the stock closing within about one percent of the offer, a pattern arbitrage desks read as confidence that the deal will close barring antitrust or financing surprises. Any spread above zero reflects time value and break risk, not a second bidding war unless a rival emerges.

Timeline and approvals

Company materials filed after the news lay out talking points for payor partners: operations stay branded Surgery Partners through closing, and day-to-day payer contacts remain the same until the transaction finishes. Management targets completion in the first quarter of 2027, subject to shareholder vote, regulatory clearance, and customary conditions. Holders should watch proxy materials for the exact meeting date and record date for voting eligibility.

Employees and affiliated physicians are outside the equity story but inside the operational risk if integrations slip. Patients should not expect facility closures solely because of the headline, though payer contracts will receive required notices under existing agreements.

Portfolio actions to consider

Tax lots matter: an all-cash sale triggers capital gains recognition at closing for taxable accounts. Investors comparing the offer to independent forecasts should model whether $23.50 beats risk-adjusted upside from staying public, especially after the company’s earlier sale of Idaho hospital interests for hundreds of millions of dollars in gross proceeds. If you hold through a fund, check the proxy voting policy of your manager rather than assuming an automatic yes vote.

Options holders face separate mechanics around deal spreads and early exercise. Anyone short the name faces buy-in risk if the stock squeezes toward the offer on low float days. None of this is personalized advice; it is the checklist holders use when a take-private price lands on the tape.

What changes if the deal breaks

Break fees and reverse termination provisions appear in the full merger agreement filed with the Securities and Exchange Commission; summary releases rarely spell out every dollar figure. If regulators delay past the first quarter of 2027 target, the stock can trade below the offer to reflect timing risk, which is when retail holders feel the most anxiety. Watch for updated guidance on Idaho asset sales and debt levels, because the company highlighted recent divestiture cash when pitching the transaction.

Index funds tracking small-cap or health-care services baskets may still hold SGRY until the delisting date; passive investors should read the fund’s merger-arbitrage policy rather than trading around the spread manually.